• Phosphatase Inhibitor Cocktail (2 Tubes, 100X): Protocol and

  2026-05-09

  The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) is designed to prevent dephosphorylation of proteins during sample preparation, ensuring accurate analysis in assays such as immunoblotting and kinase activity measurements. It is appropriate for workflows requiring preservation of phosphorylation states, but should not be used in diagnostic or medical applications. Researchers seeking quantitative control over phosphatase activity during protein extraction can rely on this reagent when following protocol-specific guidelines.

• Ceftazidime in Gram-Negative Research: Protocols & Resistanc

  2026-05-08

  Ceftazidime, a third-generation cephalosporin, is a cornerstone for Gram-negative bacterial infection research, notably in the context of multidrug resistance. This article delivers actionable workflows, troubleshooting strategies, and highlights from a pivotal epidemiological study, guiding optimal deployment of Ceftazidime in both experimental and translational applications.

• SARS-CoV-2 N Protein Suppresses GADD34-Mediated Innate Immun

  2026-05-07

  This study uncovers a novel mechanism by which the SARS-CoV-2 nucleocapsid (N) protein inhibits host innate immunity. By sequestering GADD34 mRNA into atypical stress granule-like foci, the N protein impairs IRF3 nuclear translocation and interferon gene activation, revealing a sophisticated viral strategy for immune evasion.

• BIIE 0246: Applied Use in Neuropeptide Y Y2 Receptor Antagon

  2026-05-07

  BIIE 0246 empowers researchers to dissect neuropeptide Y Y2 receptor pathways with unmatched selectivity, enabling robust exploration of feeding, anxiety, and neurocardiac mechanisms. This guide translates frontier findings into actionable protocols, troubleshooting, and strategic advantages for translational neuroscience and metabolic research.

• O-GlcNAcylation Modulates Ferroptosis in Preeclampsia via HU

  2026-05-06

  This study reveals that O-GlcNAc modification of HUWE1 regulates the ubiquitination and degradation of transferrin receptor 1 (TfR1), suppressing ferroptosis and supporting trophoblast syncytialization in preeclampsia. These mechanistic insights highlight a novel O-GlcNAc–HUWE1–TfR1 pathway, suggesting new directions for targeted placental and ferroptosis research.

• Tunicamycin: N-Glycosylation Inhibitor for Advanced ER Stres

  2026-05-06

  Tunicamycin’s precise N-glycosylation inhibition empowers researchers to dissect ER stress, inflammation suppression, and protein homeostasis in both cellular and animal models. This article delivers actionable workflows, optimization tips, and a translational bridge from the latest C. elegans cadmium resistance study to mammalian assay design.

• RITA (NSC 652287): Applied Workflows in Renal Carcinoma Rese

  2026-05-05

  RITA (NSC 652287) enables highly selective p53 activation and robust cytotoxicity in renal carcinoma models, standing out for its nanomolar potency and reliability in apoptosis and xenograft workflows. This guide details practical protocols, troubleshooting, and unique insights from recent research to maximize experimental success.

• LMO2-LDB1 Complex Drives AML Progression: Mechanistic Insigh

  2026-05-05

  This study elucidates the oncogenic role of the LMO2-LDB1 protein complex in acute myeloid leukemia (AML), demonstrating that LDB1 is essential for AML cell proliferation and survival. The findings highlight the potential of targeting this complex for therapeutic intervention.

• Applied Workflows with S-Adenosylmethionine for Methylation

  2026-05-04

  S-Adenosylmethionine (Ademetionine) is a cornerstone reagent for methylation studies in neuroscience and epigenetics, offering unmatched versatility in DNA, RNA, and protein methylation assays. This article details optimized protocols, advanced troubleshooting, and strategic insights for leveraging SAM in experimental and translational research.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-05-04

  Schwartz's dissertation introduces improved in vitro methods for accurately distinguishing between cell proliferation arrest and cell death in response to cancer drugs. This technical innovation refines drug efficacy assessment and has practical implications for optimizing preclinical workflows in cancer pharmacology.

• Vincristine Sulfate: Strategic Mechanisms in Translational O

  2026-05-03

  This article delivers a systems-level analysis of vincristine sulfate’s mechanistic power as a microtubule disrupter, while equipping translational researchers with strategic guidance for experimental design and clinical translation. Integrating recent literature, competitive benchmarking, and evidence-backed protocol parameters, we highlight how APExBIO’s Vincristine sulfate advances cancer research and drug development, moving beyond conventional summaries to chart new directions for oncology workflows.

• α-Amanitin: Elevating Transcriptional Regulation Research

  2026-05-02

  α-Amanitin empowers researchers to dissect RNA polymerase II-dependent processes with unmatched specificity. Discover precise workflows, real-world troubleshooting, and protocol enhancements that leverage APExBIO’s validated α-Amanitin for advanced gene expression pathway analysis and developmental investigations.

• Risedronate Sodium: Precision Targeting of Bone and Tumor Mi

  2026-05-02

  Explore the advanced use of Risedronate Sodium as a FPP synthase inhibitor in bone metabolism and cancer research. This article reveals novel insights into microenvironment modulation, protocol optimization, and translational applications distinct from existing reviews.

• MBD2c Modulates mtDNA Transcription and Drug Resistance in T

  2026-05-01

  This study reveals that the mitochondrial-localized isoform MBD2c enhances mtDNA transcription and mitochondrial respiration in triple-negative breast cancer (TNBC) cells, directly linking epigenetic regulation to metabolic adaptation and drug resistance. The work identifies previously uncharacterized mechanisms underlying mitochondrial gene expression control, with implications for targeting metabolic vulnerabilities in cancer.

• Optimizing Gene Delivery: EZ Cap™ Cy5 EGFP mRNA (5-moUTP) in

  2026-04-30

  Explore how EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers next-generation, non-viral gene delivery in blood cell therapy. This article goes beyond dual-fluorescence tracking to dissect electroporation strategies, immune evasion, and practical workflow design.

423 records 17/29 page Previous Next First page 上5页 1617181920 下5页 Last page